163 related articles for article (PubMed ID: 7238443)
1. Estrogen receptors and breast cancer.
Nicholson RI; Griffiths K; Blamey RW; Bishop HM; Haybittle JL
Environ Health Perspect; 1981 Apr; 38():143-6. PubMed ID: 7238443
[TBL] [Abstract][Full Text] [Related]
2. Relationship between primary breast tumor receptor status and patient survival.
Blamey RW; Bishop HM; Blake JR; Doyle PJ; Elston CW; Haybittle JL; Nicholson RI; Griffiths K
Cancer; 1980 Dec; 46(12 Suppl):2765-9. PubMed ID: 7448717
[TBL] [Abstract][Full Text] [Related]
3. [Hormonreceptors in the therapy concept of breast cancer (author's transl)].
Jonat W; Maass H
Arch Geschwulstforsch; 1981; 51(7):637-41. PubMed ID: 7337546
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptors and long-term prognosis in breast cancer.
Aamdal S; Børmer O; Jørgensen O; Høst H; Eliassen G; Kaalhus O; Pihl A
Cancer; 1984 Jun; 53(11):2525-9. PubMed ID: 6713348
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptors in primary breast cancer.
Neifeld JP; Lawrence W; Brown PW; Banks WL; Terz JJ
Arch Surg; 1982 Jun; 117(6):753-7. PubMed ID: 7082164
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
[TBL] [Abstract][Full Text] [Related]
7. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
8. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy.
Campbell FC; Blamey RW; Elston CW; Morris AH; Nicholson RI; Griffiths K; Haybittle JL
Lancet; 1981 Dec; 2(8259):1317-9. PubMed ID: 6118718
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
10. Node-negative breast cancer treated by modified radical mastectomy without adjuvant therapies: variables associated with disease recurrence and survivorship.
Huseby RA; Ownby HE; Frederick J; Brooks S; Russo J; Brennan MJ
J Clin Oncol; 1988 Jan; 6(1):83-8. PubMed ID: 3335894
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
Gapinski PV; Donegan WL
Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial.
Hubay CA; Pearson OH; Marshall JS; Stellato TA; Rhodes RS; DeBanne SM; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Breast Cancer Res Treat; 1981; 1(1):77-82. PubMed ID: 6756509
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
15. The prediction of hormonal dependency of mammary cancer.
Block GE; Jensen EV; Polley TZ
Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptors in primary breast cancer.
Hähnel R; Woodings T; Vivian AB
Cancer; 1979 Aug; 44(2):671-5. PubMed ID: 476576
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients.
Crowe JP; Hubay CA; Pearson OH; Marshall JS; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; McGuire WL
Breast Cancer Res Treat; 1982; 2(2):171-6. PubMed ID: 7171837
[TBL] [Abstract][Full Text] [Related]
20. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
